Compare BGLC & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGLC | BNGO |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 11.6M |
| IPO Year | 2019 | 2018 |
| Metric | BGLC | BNGO |
|---|---|---|
| Price | $2.20 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 5.5K | ★ 267.9K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.78 | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | $9,510,646.00 | ★ $12,000,735.00 |
| Revenue This Year | N/A | $16.19 |
| Revenue Next Year | N/A | $33.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 26.26 |
| 52 Week Low | $1.92 | $1.06 |
| 52 Week High | $15.19 | $5.50 |
| Indicator | BGLC | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 52.09 |
| Support Level | $2.12 | $1.07 |
| Resistance Level | $2.73 | $1.64 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 12.55 | 29.73 |
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.